THIORIDAZINE IN THE TREATMENT OF HOSPITALIZED ADOLESCENTS
Abstract
1. Twenty adolescent psychiatric inpatients have received 100-800 mgm. total daily doses of thioridazine for varying times over a 2-year period while resident in a dynamically oriented, intensive treatment unit.
2. The use of thioridazine, as part of a more comprehensive plan of active treatment, has benefitted selected patients with anxiety as a basic part of their syndromes by promoting freer interaction with peers and therapeutic staff.
3. The only side effects we could attribute to the drug were a readily reversible parkinsonian syndrome on higher doses (400-800 mgs. total, daily) and subjective somnolence in most patients; the latter appeared not significantly to interfere with the patients' general psychomotor functions.
4. We conclude that both the anxiety-reducing effects of thioridazine plus its exceptionally low incidence of side effects among our patients justifies the conclusion that it is a highly effective neuroleptic agent for adolescent patients under the conditions in which we have used it(6, 7).
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
